Bill Sibold
Principal executive officer pay for Bill Sibold, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) FY2023–FY2025
Beat peersTSR 152% vs peer group 36% over FY2023–FY2025
Aligned: paid up as stock roseCAP $24,201,400→$84,097,793 while $100 invested went $208.00→$524.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $32.3M | $24.2M |
| FY2024 | $12.2M | $30.7M |
| FY2025 | $19.2M | $84.1M |
The company's "$100 invested" index ran $208.00 at FY2023 → $524.00 by FY2025 — an annualized return of 58.7%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 58.7%/yr at MDGL ( FY2023–FY2025). See the CEO track-record ranking for context.